CSPC PHARMA (01093.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec25

Cai Dongchen Increases Holdings in Stone Pharmaceutical Group

09:40

Dec23

Stone Pharmaceutics Receives Clinical Trial Approval Notice for Daratumumab Injection

08:51

Sontek, China Pharmaceutical, and Huidai Acquisition-Z Disclose Latest Shareholder Rights

00:06

Dec22

Chairman Cai Dongchen of Stone Pharmaceutical Group Increased Shareholding to 25.26%

11:27

Dec19

Jade Pharmaceutical's SYH2085 Approved for Clinical Trials in China

13:18

Dec18

Sukoddju Injection Phase III Clinical Trial Achieves Positive Results for Severe Plaque Psoriasis Treatment

10:20

Schedules & Filings

Schedules

Filings

Nov20

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 7.234 B, Net Income 1.053 B, EPS 0.0921

Nov18

Distribution Plan(CST)

Cash dividend 0.14 HKD

Oct20

Distribution Plan(CST)

Cash dividend 0.14 HKD

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change